FASEB J. Avanti Polar Lipids
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.08-105940.
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
fj.08-105940v1
22/12/4248    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cai, Z. P.
Right arrow Articles by Becker, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cai, Z. P.
Right arrow Articles by Becker, L. C.
(The FASEB Journal. 2008;22:4248-4257.)
© 2008 FASEB

Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency

Zheqing P. Cai*,1, Zhenyun Shen{dagger}, Luc Van Kaer# and Lewis C. Becker*

* Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;

{dagger} Department of Thoracic Surgery, Peking University Third Hospital, Beijing, China; and

{ddagger} Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

1Correspondence: 720 Rutland Ave., Ross 333, Baltimore, MD 21205, USA. E-mail: czheqin1{at}jhmi.edu

The ubiquitin-proteasome system plays an important role in many cellular processes through degradation of specific proteins. Low molecular mass polypeptide 2 (LMP-2 or β1i) is one important subunit of the immunoproteasome. Ischemic preconditioning (IPC) activates cell signaling pathways and generates cardioprotection but has not been linked to LMP-2 function previously. LMP-2 knockout mice (C57BL6 background) and wild-type C57BL6 mice were subjected to 30 min of ischemia (I-30) and 120 min of reperfusion (R-120) with or without preceding IPC (10 min of infusion and 5 min of reperfusion). IPC significantly increased left ventricular developed pressure and decreased infarct size in wild-type mice, but this protective effect of IPC was lost in LMP-2 knockout mice. IPC-mediated degradation of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and activation of the downstream protein kinase Akt were impaired in LMP-2 knockout hearts. The impairment of PTEN degradation was associated with defective immunoproteasomes and decreased proteolytic activities. When LMP-2 knockout mice were pretreated with the PTEN inhibitor bpV(HOpic), cardiac function was significantly improved, and myocardial infarct size was significantly reduced after I-30/R-120. In conclusion, LMP-2 is required for normal proteasomal function and IPC induction in the heart. Its action may be related to PTEN protein degradation.—Cai, Z. P., Shen, Z., Van Kaer, L., Becker, L. C. Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency.


Key Words: ubiquitin-proteasome system • reperfusion injury • ubiquitin • phosphatase and tensin homologue deleted on chromosome 10 • PTEN • Akt




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
H. Luo, J. Wong, and B. Wong
Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy
Cardiovasc Res, January 15, 2010; 85(2): 347 - 356.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. Tsukamoto, T. Minamino, and M. Kitakaze
Functional alterations of cardiac proteasomes under physiological and pathological conditions
Cardiovasc Res, January 15, 2010; 85(2): 339 - 346.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Su and X. Wang
The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective
Cardiovasc Res, January 15, 2010; 85(2): 253 - 262.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. R. Powell and A. Divald
The ubiquitin-proteasome system in myocardial ischaemia and preconditioning
Cardiovasc Res, January 15, 2010; 85(2): 303 - 311.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The Federation of American Societies for Experimental Biology.